Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin

Experimental Oncology

Volumn 31, Issue 3, 2009, Pages 140-143

  Rusetskaya, N V ^a   Lukyanova, N Yu ^a   Chekhun, V F ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Doxorubicin; Liposome; MCF 7

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXORUBICIN; METALLOTHIONEIN; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR;

ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG FORMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; METALLOTHIONEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, STEROID; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72449139148     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Baryshnikov AY, Stepanova EV. The problems of drug resistance. Materials of third annual Russian oncological conference, Sankt-Petersburg, Russia. 1999: 14-17 (In Russian).
2. Ponomareva OV, Kindzelskiy LP, Kulik GI, et al. Treatment of non-Hodgkin lymphoma patients with liposomal doxorubicin. Oncology 2004; 4: 274-277 (In Russian).
3. Richardson VJ, Ryman BE. Effect of liposomally trapped antitumor drugs on a drug-resistent mause lymphoma in vivo. Br J Cancer 1992; 84: 1909-1915
4. Ni J, Hollander D. Application of the MTT-assay to functional studies of mouse intestinal intraepithelial lymphocytes. J Clin Lab Anal 1996; 10: 42-52. (Pubitemid 26049787)
5. Chekhun VF, Lukyanova NYu, Yurchenko OV, et al. The Role of Expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp Oncol 2005; 27: 191-195
6. Ormerod MG, eds. Flow cytometry - handbooks, manuals, etc. II Series. Oxford: Oxford University Press, 2000: 277 p.
7. Lukyanova NYu, Rusetskya NV, Tregubova NA, et al. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxsorubicin. Exp Oncol 2009; 31: 87-92.
8. Cheng G, Zhu H, Sun L. The expression of multiple drug resistance associated genes ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 2004; 2: 87-90.
9. Dziegiel P. Expression of metallothioneins in tumor cells. Pol J Pathol 2004; 55: 3-12.
10. Bozhok AA, Semiglazov VF, Semiglazov VV. Breast cancer prognostic factors. Modern Oncol 2007; 1: 74-78 (In Russian).
11. Kopnin BP. Target of oncogenes tumor supressors action: the key of understanding the mechanism of cancerogenesis. Biochem 2000; 65: 5-33 (In Russian).